Mykare AI builds software for hospitals and clinics that automates patient calls, appointment booking, follow-ups, feedback, and CRM updates. The company has now added $1 million to its seed financing from Papa.com cofounders Andrew Parker and Alfredo Vaamonde plus a Middle Eastern family office, taking the round total to $3.2 million. The pitch is simple: healthcare providers lose too much revenue and patient trust in the handoff between enquiry, booking, and post-visit communication. Founded in 2022 by Senu Sam, Rahmatulla TM, and Joash Philipose, the startup is betting that an AI-native operating layer can fix that mess faster than more admin staff can.
What does Mykare AI actually do?
Mykare AI sells Kare OS — a patient-engagement and sales layer for healthcare providers that works across voice and text. A patient can start with a phone call or message, get greeted in the facility’s own script, ask questions, get routed to the right doctor or workflow, then book, reschedule, cancel, or follow up without waiting for a human to pick up. The system also writes the outcome back into the clinic’s CRM, so staff aren’t stuck copying notes between tools.
The product isn’t just one receptionist bot. It’s split into specialized agents for front-desk enquiries and inbound lead conversion. It also handles outbound follow-up, patient experience, guest relations, and international patient support. One customer might use it to answer routine calls 24/7. Another might use it to chase leads, confirm bookings, collect feedback, or coordinate post-treatment follow-ups without adding headcount.
There’s also a more ambitious layer here. Mykare’s product pages show workflows for medical-report verification and second-opinion coordination. They also cover language translation, visa-letter support, hotel and flight coordination, and local logistics for international patients. That’s a lot broader than basic scheduling software. It hints at why the startup thinks healthcare needs vertical AI rather than a generic call bot with a medical script taped on top.
Mykare is also leaning hard into trust. It says its responses are doctor-trained and QA-validated, with human-supervised escalation when needed, plus HIPAA, VAPT, and DPDP compliance messaging on its site. It also supports 20+ languages in voice and text. That matters.
Who founded Mykare AI and why did it pivot?
The company started as a healthcare operator, not a software vendor
Mykare didn’t begin life as a B2B SaaS startup. It first operated as a patient-facing business that connected people to hospitals for affordable, planned care, especially surgeries, and handled coordination around that journey. That history matters because the October 2025 pivot to B2B wasn’t a random AI rebrand. The team had already spent about 2.5 years inside the workflow problems it’s now productizing.
Why Senu Sam had a real wedge
Sam’s background gave the company its wedge. He brought more than 13 years of healthcare sales experience, and his father’s surgery during the COVID-19 period exposed the gaps in transparency, coordination, and patient support firsthand. That mix — distribution experience plus personal frustration — is more useful in this category than a generic AI résumé.
What the team learned before the pivot
Before launching the AI-first version, the founders had already partnered with 300+ facilities across 12 cities and served more than 100,000 patients through the earlier model. That operating history helps explain the current product design. The company didn’t start with “let’s build a voice agent.” It started with “where exactly does patient conversion break?” and worked backward from there.
Traction after the pivot
The newer Mykare AI product is already live. Sam said the agents are embedded in 30–35 larger healthcare facilities, another 45 clinics have signed up for implementation, and the company wants to touch 100 clinics soon. The business is active across Delhi NCR, Mumbai, Bengaluru, and Hyderabad. It also has provider relationships spanning India, the US, the UK, and the Middle East — including a large oncology clinic chain in the US, a large dental chain in the UK, and talks with a major dental chain in Qatar.
The funding details
This latest cheque is an extension of Mykare’s 2023 seed round. Back then, the startup had raised $2.2 million from investors including OnDeck ODX and Avaana Seed; the new $1 million closes the round at $3.2 million. The money is earmarked for stronger AI capabilities and faster product development. It will also support deeper expansion in markets where the company already has some commercial footing.
How Mykare AI stacks up against competitors
Mykare isn’t entering an empty market. In the US, Hyro, Keona’s Kara, Relatient’s Dash Voice AI, Voxy, and CuroAI are all pushing variations of the same promise: answer more calls, automate scheduling, cut wait times, and reduce staff load. Some are clearly built for larger health systems, with deeper EHR integrations, broader contact-center tooling, or heavy compliance and audit features out of the box.
Mykare’s edge looks different. It’s going after small and mid-sized hospitals and clinics, not just giant enterprise buyers. It also blends voice, text, CRM updating, multilingual support, and international patient workflows in one story. That makes it feel less like a narrow scheduling bot and more like a revenue-and-retention layer for fragmented providers. The real incumbent, honestly, is still the old stack: front-desk staff, missed calls, generic CRMs, IVR menus, and a lot of manual follow-up that simply doesn’t happen.
Why does Mykare AI funding matter?
This isn’t a giant round. But it’s an important one.
Because Mykare raised it after a major business-model shift, the new money reads like a vote of confidence in the B2B thesis rather than a reward for the old marketplace model. Investors aren’t just funding more hospital partnerships here. They’re funding software that the company believes can scale across many providers without rebuilding operations city by city.
The investor mix matters too. Papa.com’s cofounders bring healthtech operating credibility from the US, while the Middle Eastern family office lines up with the regions where Mykare is already trying to deepen its footprint. That doesn’t guarantee international breakout. But it does suggest the company is trying to become a cross-border healthcare operations product, not a local India-only tool. That’s a bigger swing.
Is healthcare AI in India big enough for this bet?
The short answer is yes — at least big enough to matter.
A BCG and B Capital report, cited widely in India startup coverage, pegged India’s healthtech revenue opportunity at $37 billion by 2030. On the global side, Statista forecasts the worldwide digital health market will reach about $219.6 billion by 2030. That doesn’t mean every healthcare AI startup wins. It does mean the budget pool for software that improves patient access, booking, retention, and automation is getting real.
Buyer behavior is changing now. Healthcare providers are finally treating patient access as an operations problem that software can improve, not just a staffing problem to paper over. That’s why so many competitor products now sell 24/7 call handling and rules-based scheduling. They also pitch AI-to-human handoff, multilingual support, and audit trails as core features rather than extras. Mykare’s timing makes sense because the category itself has become easier to explain — and easier to buy.
Where Mykare AI goes next
Mykare AI still has a lot to prove. Voice AI in healthcare looks great in a demo, but real scheduling logic, compliance, escalation, and patient trust are where products usually get exposed.
Still, this round gives Mykare enough room to make its case properly. If the company can turn its early clinic deployments into repeatable, measurable outcomes — not just answered calls, but more booked visits and better retention — then Mykare AI could end up as one of the more interesting healthtech pivots to watch from India over the next year.
Read how Incuspaze raised ₹150 crore in funding led by Bharat Value Fund to expand its managed workspace platform, pursue acquisitions, invest in workplace technology, and accelerate its IPO plans for FY29.
FAQ
- What funding did Mykare raise? Mykare raised an additional $1 million in a bridge extension that closed its seed financing at $3.2 million. The new backers were Papa.com cofounders Andrew Parker and Alfredo Vaamonde, along with a Middle Eastern family office, and the earlier 2023 seed included OnDeck ODX and Avaana Seed.
- How does Mykare AI work for hospitals and clinics? Mykare AI works as a voice-and-text operating layer that handles patient enquiries, books or reschedules appointments, follows up leads, collects feedback, and writes outcomes back into CRM systems. The product is built around multiple specialized agents, not one generic bot. It also supports international-patient tasks like translation, second-opinion coordination, and travel-related assistance.
- Who founded Mykare and what is the founders’ background? Mykare was founded in 2022 by Senu Sam, Rahmatulla TM, and Joash Philipose. Sam brought more than 13 years of healthcare sales experience, and the founding insight came partly from the team’s earlier patient-services business and from the friction Sam saw around his father’s surgery during the pandemic period.
- Is Mykare a healthcare marketplace or a healthcare AI company? Right now, it’s best understood as a healthcare AI company selling workflow automation to providers. It began as a consumer-facing care-coordination business, but in October 2025 it pivoted to a B2B model focused on clinics and hospitals that want an AI-native layer for patient access, engagement, and operations.
